An open label study to evaluate the safety, tolerability, and subjective effects of two dimethyltryptamine (DMT) and harmala alkaloid containing formulations in healthy volunteers

This small open-label trial (n=8) will test the safety of two doses of the ayahuasca brew containing DMT (1.0mg to 1.4mg/kg). The trial is sponsored by Psychae and is done in collaboration with St. Vincent’s Hospital in Melbourne Australia.

Trial Details

Initially, two orally administered DMT (1.0mg/kg) and harmala alkaloid formulations (4mg/kg) will be provided in separate single-dose sessions to 8 healthy volunteers (with prior experience of these substances). After this data is collected, an interim assessment of the psychedelic effect and safety parameters will occur, with one of the formulations being chosen for the next dosage level. The amount given to the 8 participants will be increased to: DMT (1.4mg/kg) and harmala alkaloids (5.6mg/kg). Participants will be given both formulations in a cross-over design (16 psychedelic sessions in total), with a 2-week washout between treatments. Initial treatment group assignment will be randomised. Post-monitoring will occur to assess the more chronic effects of the treatments.

NCT Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.